Product
Prevenar 13
Aliases
Prevenar 13™
5 clinical trials
7 indications
Indication
Pneumococcal InfectionsIndication
Streptococcus pneumoniae infectionIndication
SepsisIndication
InfectionsIndication
PneumococcalIndication
Intestinal DiseasesIndication
InflammatoryClinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Active-comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (PNEU-PED-EU-1)Status: Completed, Estimated PCD: 2021-08-05
Clinical trial
Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants Aged 2 Months (at Least 6 Weeks) and 3 MonthsStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Active-comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2)Status: Completed, Estimated PCD: 2021-10-29
Clinical trial
Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis SurvivorsStatus: Completed, Estimated PCD: 2023-08-31
Clinical trial
Phase IIb Multicenter Randomized Comparative Study of Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for Chronic Inflammatory Bowel DiseaseStatus: Terminated, Estimated PCD: 2019-08-06